Novo Nordisk A/S (ADR) (NVO) is Downgraded by BofA/Merrill to Neutral

Novo Nordisk A/S (ADR) (NVO) was Downgraded by BofA/Merrill to ” Neutral”. Earlier the firm had a rating of “Buy ” on the company shares. BofA/Merrill advised their investors in a research report released on Aug 8, 2016.

Novo Nordisk A/S (ADR) closed down -5.33 points or -9.66% at $49.87 with 79,91,070 shares getting traded on Friday. Post opening the session at $49.68, the shares hit an intraday low of $48.88 and an intraday high of $50.3 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery development manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Company’s diabetes care segment covers insulins GLP-1 other protein-related products (such as glucagon protein-related delivery systems and needles) oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark and internationally in the United States France China and Brazil.

Novo Nordisk A/S (ADR)

Leave a Reply

Novo Nordisk A/S (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novo Nordisk A/S (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.